Protein kinase Cι-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218330 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Shichuan Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, 610041, China; Department of Biotherapy, Cancer Center an…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase C, Tumor-Associated Macrophages. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Sichuan Provincial Science and Technology Support Program, Health Commission of Sichuan Province, Sichuan University.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains the leading cause of cancer-related mortality. Immune checkpoint inhibitors (ICIs) targeting the programmed death-1/programmed death ligand 1 (PD-1/PD-L1) axis can induce durable tumor regression in a subset of NSCLC patients; however, most exhibit resistance to ICIs therapy. Here, we identify the protein kinase Cι (PKCι)) as a biomarker and critical mediator of poor ICIs responsiveness in NSCLC. High PKCι expression correlates with resistance to anti-PD-1 antibody (αPD1) therapy, whereas low PKCι expression are highly sensitive. PKCι-dependent resistance to αPD1 is characterized by increased tumor-associated macrophages (TAMs) infiltration and reduced CD8+T cell numbers. Mechanistically, PKCι regulated Yap1-dependent transcription of CCL7, which recruits TAMs and fosters an immunosuppressive microenvironment. In contrast, Overexpression of PKCι or CCL7 in PKCι-knockdown tumors restores TAMs infiltration and αPD1 resistance. Pharmacological inhibition of PKCι with auranofin (AF) reduces TAMs accumulation and promotes CD8+T cell infiltration by inhibiting the PKCι-Yap1-CCL7 axis. Combination therapy with AF and αPD1 triggers a CD8+T cell-dependent antitumor immune response, thereby controlling tumor growth in situ or subcutaneously. In summary, our study reveals a PKCι-mediated immunosuppressive pathway driving ICIs resistance and support PKCι inhibition as a promising strategy to enhance immunotherapy efficacy in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, 610041, China; Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan Uni…
- Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, 610041, China.
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
- Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address: zhang.yan@scu.edu.cn.
Förderung
- Sichuan Provincial Science and Technology Support Program
- Health Commission of Sichuan Province
- Sichuan University
- China Postdoctoral Science Foundation
Zitieren
APA
Hu, S., Zhao, Z., Zhao, J., Liang, Y., Zeng, L., Xia, Y., Guo, H., Jiang, L., & Zhang, Y. (2026). Protein kinase Cι-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218330
Vancouver
Hu S, Zhao Z, Zhao J, Liang Y, Zeng L, Xia Y, et al. Protein kinase Cι-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218330
BibTeX
@article{Hu2026,
author = {Hu, Shichuan and Zhao, Zichen and Zhao, Jing and Liang, Yilin and Zeng, Lingye and Xia, Yifei and Guo, Haoya and Jiang, Lili and Zhang, Yan},
title = {Protein kinase Cι-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218330}
}
EUVIMED